Discover investment opportunities in Small Cap Biotech Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Small Cap Biotech Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Small Cap Biotech Stocks using our Smart AI Filter.
3 stocks found for "Small Cap Biotech Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
0.86 | ±68.1% | -38.2 | 0.00% | |||
1.09 | ±40.2% | -7.8 | 0.00% | |||
1.23 | ±78.1% | 24.1 | 0.00% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: What growth potential do small cap biotech stocks like ARWR have?
A: Small cap biotech stocks like ARWR often offer significant growth potential due to innovative drug developments and unmet medical needs. However, their performance is highly volatile, often dependent on regulatory approvals and clinical trial outcomes.
Q: Do small cap biotech stocks such as FGEN offer dividend income?
A: Small cap biotech companies like FGEN typically do not offer dividends, as they reinvest earnings into research and development to fuel growth and advance clinical trials.
Q: How have regulatory changes impacted small cap biotech stocks like JNCE?
A: Regulatory changes can significantly impact JNCE by influencing timelines for drug approvals and potentially altering the cost and risk profile of developing therapies.
Q: What are the risks of investing in small cap biotech stocks such as ONTX?
A: Risks include high volatility, dependency on clinical trial outcomes, regulatory approval uncertainty, and potential capital needs, which can lead to stock dilution or financial strain.
Q: How does the economic cycle affect small cap biotech stocks like VKTX?
A: Economic cycles have less direct impact on VKTX due to its dependence on research breakthroughs and regulatory approvals rather than market demand; however, broader market downturns can affect overall investor sentiment.
Q: What competitive advantages do small cap biotech companies such as XENE have?
A: XENE may benefit from having novel therapeutic approaches and niche specialization, which can provide advantages over larger firms in addressing specific, often overlooked medical needs.
The heavy selling pressure might have exhausted for Soleno Therapeutics (SLNO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Read moreSoleno Therapeutics Inc. SLNO shares fell on Friday following a short report from Scorpion Capital, which criticized the company's only product, Vykat XR, as overpriced and potentially unsafe for children with Prader-Willi syndrome (PWS).
Read moreThe U.S. Food and Drug Administration (FDA) on Wednesday approved Soleno Therapeutics, Inc.'s SLNO Vykat XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, for hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome (PWS).
Read more